China Isotope & Radiation Corporation Announces Full Completion and Commissioning of Asia’s Largest Radioactive Source R&D and Production Base
Key Points
- The company’s subsidiary, Chengdu Gaotong Isotope Co., Ltd. (CNNC), has completed Phase II of its radioactive source R&D and production base and received a radiation safety permit.
- Production lines for Californium-252, Caesium-137, and Americium-241 have officially commenced operations, fully meeting diversified market demands.
- The base now operates 14 radioactive source production lines, including Carbon-14 and Krypton-85 sources, capable of producing over 70 types of nuclides.
- Annual production capacity exceeds 100,000 units, targeting applications in industry, agriculture, medicine, national defense, and aerospace.
- This marks the full completion and commissioning of the largest radioactive source R&D and production base in Asia.
- The base upgrade accelerates China’s transition from old to new sealed radioactive source production capacity and strengthens its leadership in R&D and industrial applications.
- With the expanded capacity, the company will intensify efforts to serve international markets, including Belt and Road countries.
- The announcement was made on 10 June 2026, with the Board led by Chairman Xiao Yafei.
Detailed Analysis for Investors
China Isotope & Radiation Corporation has reached a significant milestone in its business development, as its subsidiary Chengdu Gaotong Isotope Co., Ltd. has completed and fully commissioned Phase II of its radioactive source R&D and production base. The completion and approval to add licensed items to its radiation safety permit signal the start of official production for strategic nuclides, including Californium-252, Caesium-137, and Americium-241. These products are high-value radioactive sources used extensively in industrial, agricultural, medical, national defense, and aerospace sectors.
The new production base is now the largest of its kind in Asia, featuring 14 production lines and the capability to manufacture high-quality radioactive sources covering over 70 nuclide types. Its annual production capacity exceeds 100,000 units, which positions China Isotope & Radiation as a clear leader in the region and potentially globally.
From an investor perspective, this development is highly significant and could be price sensitive for several reasons:
- Market Expansion: The increase in production capacity allows the company to meet domestic demand more efficiently and aggressively pursue international markets, especially in countries aligned with China’s Belt and Road initiative.
- Technological Upgrade: The base’s completion represents an accelerated technical upgrade and modernization of China’s sealed radioactive source industry, ensuring the company remains at the forefront of innovation and production.
- Revenue Potential: With broader product offerings and higher output, China Isotope & Radiation stands to benefit from increased sales and potential new contracts domestically and overseas.
- Strategic Advantage: The company’s strengthened position in R&D and industrial application of radioactive sources could attract strategic partnerships and investments, thereby positively impacting its share price.
Shareholders should take note of these developments, as the full commissioning of the base and its enhanced production capabilities could directly impact the company’s financial performance and market valuation. The news reflects a substantial upgrade in capacity and competitive positioning, factors that typically influence share prices in the medium to long term.
Board Composition
As of the announcement date, the Board includes Chairman Xiao Yafei, executive directors Mr. Zhang Junqi and Ms. Huo Yingying; non-executive directors Mr. Chen Zan, Mr. Ding Jianmin, and Ms. Chang Jinyu; and independent non-executive directors Mr. Poon Chiu Kwok, Ms. Chen Jingshan, Mr. Lu Chuang, and Mr. An Rui.
Disclaimer
This article is for informational purposes only and does not constitute investment advice. Investors are urged to conduct their own due diligence and consult with professional advisors before making investment decisions. The information provided is based on official corporate announcements and may be subject to change.
中國同位素與輻射公司宣布：亞洲最大放射源研發及生產基地全面竣工投產
關鍵點
- 公司子公司成都高同同位素有限公司（CNNC）完成放射源研發及生產基地二期建設，並獲得輻射安全許可證。
- 鈣-252、銫-137、鋁-241等放射源生產線正式投產，全面滿足多元化市場需求。
- 基地設有14條放射源生產線，包括碳-14和氪-85，能生產超過70種核素產品。
- 年產能力超過10萬件，覆蓋工業、農業、醫療、國防、航天等領域。
- 此次竣工標誌著亞洲最大放射源研發及生產基地正式投入運行。
- 基地升級加速中國密封放射源產能轉型，鞏固國內領先地位。
- 產能釋放後，公司將加強國際市場拓展，積極服務「一帶一路」沿線國家。
- 公告於2026年6月10日發布，董事會由肖亞飛主席領導。
投資者詳細分析
中國同位素與輻射公司取得重大業務進展，其子公司成都高同同位素有限公司已完成並全面投產放射源研發及生產基地二期項目，並獲得新增許可輻射安全證。此舉標誌著公司重點核素——鈣-252、銫-137、鋁-241正式進入生產階段，這些產品在工業、農業、醫療、國防及航天領域具有高附加值和廣泛應用。
新基地現為亞洲最大放射源研發及生產基地，擁有14條生產線，可生產超過70種核素類高質量放射源產品，年產能力逾10萬件，進一步夯實公司在區域乃至全球市場的領導地位。
對股東來說，此事件極具重要性，可能對股價產生敏感影響，原因包括：
- 市場拓展：產能提升讓公司能夠更好滿足國內需求，並積極拓展國際市場，尤其是「一帶一路」沿線國家。
- 技術升級：基地竣工加速中國密封放射源產業的技術升級和現代化，確保公司保持創新和生產領先。
- 收入潛力：產品種類更豐富且產量提升，預期銷售及新訂單將帶來業績增長。
- 戰略優勢：公司在研發和產業應用上的領先地位，可能吸引戰略合作夥伴和資本，利好股價。
股東應密切關注此次基地全面投產和產能擴大，因其將直接影響公司財務表現和市場估值，此舉代表公司競爭力和產業地位大幅提升，是中長期價值提升的重要因素。
董事會組成
截至公告日，董事會成員包括主席肖亞飛，執行董事張君啟、霍瑩瑩；非執行董事陳贊、丁建民、常金玉；以及獨立非執行董事潘昭國、陳璟珊、盧創、安瑞。
免責聲明
本文僅供參考，不構成投資建議。投資者請自行做好盡職調查，並諮詢專業顧問後再作出投資決策。內容基於公司官方公告，如有更改請以最新資訊為準。
